Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Mirabegron extended-Release Tablets, 25 mg and 50 mg and therefore is eligible for 180 days of shared generic drug exclusivity for Mirabegron Extended Release Tablets, 25 mg and 50 mg.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.
Mirabegron Extended-Release Tablets USP 25mg and 50mg had annual sales of USD 2.42 bn in the United States according to IQVIA data (IQVIA MAT August 2022).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
